Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cash for clinics: a new way to boost HPV shots?

NCT ID NCT05744960

Vaccine Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving money to clinics can encourage doctors to talk about and offer the HPV vaccine more often. Some clinics get training on how to talk about the vaccine, while others get the same training plus a financial reward and monthly progress reports. The goal is to see if these rewards help more children ages 9-12 start and finish the HPV vaccine series.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

34 people

The number who actually took part.

Started

Feb 2023

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

9 to 12 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

This trial will enroll clinics and intervene with clinical staff. We will use vaccination data from children to evaluate intervention effectiveness. We will not enroll children or interact with them directly. Inclusion Criteria: Clinics are eligible if they are a pediatric or family medicine clinic in North Carolina that in the past year had: * less than 72% HPV vaccine initiation rate, * greater than or equal to 50 patients ages 9-12 * greater than or equal to 2 HPV vaccine providers * no clinic or provider-level financial incentive programs to increase system, clinic, or provider HPV vaccination rates among patients aged 9-12 in the past two years, and * no HPV vaccine provider communication trainings in the past six months. Children's medical records will be eligible to be included in the dataset if children: * are between the ages of 9-12 years at baseline and * are attributed to a participating clinic at 12- or 24-month follow-up. Exclusion Criteria: Clinics are excluded if they: * do not provide HPV vaccine to children ages 9-12 * have a specialty other than pediatrics or family medicine * had an HPV vaccine-specific financial incentive program in the past two years * had a formal HPV vaccine communication training in the past 6 months * had an HPV initiation rate greater than 72$ * had fewer than 49 patients aged 9-12 * had 1 or fewer HPV vaccine providers Children's medical records will not be eligible to be included in the dataset if children: * are not between the ages of 9-12 years at baseline * are not attributed to a participating clinic at 12- or 24-month follow-up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Human papilloma virus are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papilloma virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Human papilloma virus

Contacts and locations

Locations

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina, 27599-7590, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.